GlycoMimetics, Inc.
GLYCDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Rivipansel
Anemia, Sickle Cell
GMI-1271
Leukemia, Myeloid, Acute
GMI-1070
Sickle Cell Disease
Uproleselan
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rivipansel | Phase 3 | Anemia, Sickle Cell | - | - |
GMI-1271 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
GMI-1070 | Phase 2 | Sickle Cell Disease | - | - |
Uproleselan | Phase 2 | Multiple Myeloma | - | - |
Frequently asked questions
What is in GlycoMimetics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in GlycoMimetics, Inc.'s (GLYC) pipeline across Phase 3, Phase 2. Its lead program is Rivipansel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GlycoMimetics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for GlycoMimetics, Inc. (GLYC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GLYC biotech catalysts?→
Add GLYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GlycoMimetics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.